Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics
Company Announcements

Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics

Ocuphire Pharma ( (OCUP) ) just unveiled an update.

Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, forming a leading biotech company focused on gene therapies for inherited retinal diseases (IRDs). This strategic move will see the company renamed Opus Genetics, Inc. and trading under the ticker ‘IRD.’ With promising early data, the merger brings together a strong leadership team to advance groundbreaking therapies, while extending the cash runway into 2026. Investors can expect significant clinical milestones in 2025, including trials for LCA5, BEST1, and other ophthalmic conditions.

Learn more about OCUP stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyTwo new option listings and one option delisting on October 24th
TheFlyOcuphire Pharma price target lowered to $10 from $18 at Canaccord
TheFlyOcuphire Pharma rating placed under review at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App